Since we observed a  rapidly growing demand for prevention means, particularly vaccines, on a global basis, Virbac had to adapt his R&D capacities for both existing and new products. An essential step in this transformation phase was the construction of a new-state-of-the-art R&D center for biologicals. Virbac has a long standing presence in Taiwan and has been able to draw considerable benefits from the island’s advanced infrastructure and strong innovative industries. Based on this it became evident to invest in Taiwan to meet future needs in animal health and further strengthen the long term relationship with National Pingtung University of Science and Technology (NPUST) and Agricultural Technology Research Institute (ATRI). Virbac is also keen to maintain and develop the skills and know-how of current and future employees from the regional pool.

The main objectives of the R&D center will be to develop innovative vaccines and immune-stimulants, fight new diseases, and/or improve existing products in terms of efficacy, safety and ease of use for all species on a domestic, regional, and global scale, thereby creating a center of excellence for R&D in South East Asia. More specifically, the R&D activities will concentrate on the development of upstream and downstream processes and validated analytical tools. The ultimate objective of these activities is the mastering, registration and transfer of products to our manufacturing facilities worldwide. This project will also bring positive spin offs to Taiwan and the Virbac subsidiary.